New collaboration with Dr David Durantel’s team

Following the positive proof-of-concept data from 203 study of Vonafexor in combination with pegylated-Interferon (peg-IFN) in viremic patients with chronic hepatitis B (CHB), a new collaboration was initiated with the team of David Durantel at the International Center for Research in Infectiology (CIRI – INSERM U1111,

Read next in 'Latest news'